Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...

In addition, Paul Stoffels, who led Galapagos’ transformation into a cell therapy company, will retire from his role within ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...